Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
September 11 - 13, 2019; Stockholm, Sweden
September 11 - 13, 2019Stockholm, Sweden
ECTRIMS 2019Anti-CD19 MAb Trial Halted Early for Benefit in NMOInebilizumab is one of three new treatments for neuromyelitis optica — which have all shown striking degrees of efficacy — but are likely to be much more expensive than current mainstay therapy.
Medscape Medical News, September 13, 2019
ECTRIMS 2019Antibody Monotherapy Shows Promise in Neuromyelitis OpticaSatralizumab as monotherapy is effective vs placebo for reducing risk of relapses in patients with autoimmune neuromyelitis optica spectrum disorder (NMOSD), new research suggests.
Medscape Medical News, September 12, 2019
ECTRIMS 2019MESEMS: No Reduction in MS Lesions With Stem Cell TherapyAlthough the primary outcome of a multinational phase 2 study was negative, researchers said promising secondary findings support the use of mesenchymal stem cells in patients with MS.
Nearly 1 in 5 Patients Referred for MS Are MisdiagnosedResearchers reveal the prevalence, most common alternative diagnoses, and factors associated with misdiagnosis of patients
with an established multiple sclerosis diagnosis.
